Discontinued — last reported Q1 '24
Products & Services · Liabilities
Lenvima — Liabilities
Merck & Co. Lenvima — Liabilities decreased by 50.0% to $125.00M in Q1 2024 compared to the prior quarter. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2018
Last reportedQ1 2024
Rolls up toTotal Liabilities
How to read this metric
Lower liabilities generally indicate reduced financial risk and fewer outstanding obligations to partners.
Detailed definition
The total financial obligations arising from a product collaboration agreement that are currently recorded on the balanc...
Peer comparison
Standard liability reporting for joint ventures or co-marketing agreements in the life sciences sector.
Metric ID:
mrk_segment_alliance_revenue_lenvima_liabilitiesHistorical Data
4 periods
| Q1 '23 | Q3 '23 | Q4 '23 | Q1 '24 | |
|---|---|---|---|---|
| Value | $125.00M | $250.00M | $250.00M | $125.00M |
| QoQ Change | — | +100.0% | +0.0% | -50.0% |
| YoY Change | — | — | — | +0.0% |
Range$125.00M – $250.00M
Avg YoY Growth+0.0%
Median YoY Growth+0.0%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Merck & Co.'s lenvima — liabilities?
- Merck & Co. (MRK) reported lenvima — liabilities of $125.00M in Q1 2024.
- What does lenvima — liabilities mean?
- The total outstanding financial obligations owed to a partner for a specific product collaboration.